| Publication number |
CLPUB00659 |
|---|
| Authors |
Turner-Gillies E., Shapiro B.A., Tian F. |
|---|
| Title |
Generation of cell lines capable of producing high-titer viral stocks for use in vaccine manufacture and gene therapy. |
|---|
| Citation |
(In) ATCC application note AP-082021-v01; pp.1-8; ATCC; Manassas (2021) |
|---|
| Web pages |
https://www.atcc.org/resources/application-notes/generation-of-cell-lines-capable-of-producing-high-titer-viral-stocks |
|---|
| Abstract |
Antiviral vaccines are essential for preventing epidemic disease; however,
the production of these therapeutics is often limited by low-yielding
manufacturing processes. Similarly, the development of gene therapies is
constrained during the large-scale production of viral vectors, such as
adeno-associated virus (AAV) delivery platforms for gene transfer. To
speed the pace of these various areas of bioproduction, ATCC addressed the
need for efficient viral replication by optimizing three cell lines
commonly used in virus manufacturing. Here, we used CRISPR/Cas9 gene-
editing technology to develop STAT1 and BAX knockout cell lines capable of
producing high-titer viral stocks. These newly created cell lines can
produce model clinical viruses and adeno-associated viruses at titers much
higher than the parental cell lines, providing an efficient method for
biopharmaceutical companies to increase production while reducing
associated costs.
|
|---|
| Cell lines |
CVCL_B0NB; 293.STAT1 BAX KO CVCL_YZ44; MDCK.STAT1 KO CVCL_YZ45; Vero.STAT1 KO |
|---|
